Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment pro…
Biotechnology
DK, Bagsvaerd [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -14.59 | 0.70 | 0.82 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 31.82 | 0.58 | 0.44 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -7.07 | 22.18 | 23.87 | |
| Cash | -69.19 | 2.09 | 6.77 | |
| Capex | 45.12 | -2.02 | -3.68 | |
| Free Cash Flow | -22.86 | 1.19 | -1.54 | |
| Revenue | -0.67 | 14.65 | 14.75 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.04 | 0.85 | 0.85 | |
| Operating Margin | 22.05 | 0.50 | 0.41 | |
| ROA | 21.70 | 0.08 | 0.07 | |
| ROE | 24.63 | 0.26 | 0.21 | |
| ROIC | 28.67 | 0.21 | 0.16 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of NVO is permitted for members.
5
Growth
The "Growth Entry" for the Focus of NVO is permitted for members.
6
Leverage & Liquidity